Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is APBI appropriate for patients with rare tumor histology (mucinous, medullary, or tubular) if they meet all other suitability criteria?
Answer from: Radiation Oncologist at Community Practice
If phenotype right then it is tubular and mutinous are ER positive low grade tumor and are good candidates for APBI.
Comments
Radiation Oncologist at Cleveland Clinic
Agreed, these patients are good candidates for APB...
Radiation Oncologist at Mallory Radiotherapy, PLLC
Hi, thanks for your replies! I asked this question...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
Medullary is Associated with BRCA 1 mutation and c...
2481
2482
2483
Sign in or Register to read more
7005
Related Questions
Do young, early-stage breast cancer patients with pCR to chemoimmunotherapy still benefit from PMRT?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
Do you recommend self-breast exams to your patients with history of breast cancer in addition to imaging surveillance?
Are there additional risks associated with PMRT for a patient with prior lympho-venous bypass surgery?
Can a patient receiving post-mastectomy radiation therapy be treated concurrently with total body UVA or UVB light therapy for psoriasis?
Would you recommend PMRT for multifocal IDC with extensive LVI and 1 SLN with ITCs?
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
How would you approach radiation for an elderly patient with pT2N1 TNBC s/p MRM and ALND who refused chemo-immunotherapy?
Agreed, these patients are good candidates for APB...
Hi, thanks for your replies! I asked this question...
Medullary is Associated with BRCA 1 mutation and c...